Clinical Lung Cancer · 2014 · 13 citations · 36 references
MedicineOncologyPharmacologyClinical PharmacologyImmunotherapyMolecular OncologyClinical TrialsDose EscalationEfficacy EvaluationResponse AssessmentTreatment Response MonitoringEgfr InhibitionEgfr Mutation TestingErlotinib TherapyPhase Ii InvestigationRechallenge ResponsesTargeted Therapy ResponseTherapeutic RechallengeTherapeutic Trials
36
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok, Yi‐Long Wu, Sumitra Thongprasert et al. · New England Journal of Medicine · 2009 · 8.2K citations · Full text
Medicine, Oncology, Pharmacology +13
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Alan Sandler, Robert J. Gray, Michael C. Perry et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +13
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations
Medicine, Oncology, Pharmacology +13